Press Enter to search · ESC to close

Macro

China NMPA Approves Sinovent’s Iminexifor for Hospital-Acquired Pneumonia

China’s National Medical Products Administration has approved iminexifor for injection (brand name Fonokai), a Class 1 innovative drug filed by Suzhou Sinovent Pharmaceutical Technology, for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). The drug is indicated for patients aged 18 and older with HABP/VABP caused by susceptible Gram-negative bacteria including Klebsiella pneumoniae, the Acinetobacter calcoaceticus-baumannii complex, Pseudomonas aeruginosa and Escherichia coli.

Share

Related News

新云社 share card
Long-press image above → Save to Photos / Share
Pitch us Feedback